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Immunity after T Cell–Depleted Allogeneic
Transplantation Requires Symptomatic
Virus Reactivation
Eva Distler,1 Elke Schnu¨rer,1 Eva Wagner,1 Charis von Auer,1 Bodo Plachter,2
Daniela Wehler,1 Christoph Huber,1 Karin Kolbe,1 Ralf Georg Meyer,1 Wolfgang Herr1Reactivated varicella-zoster virus (VZV) infection causes herpes zoster and commonly occurs after alloge-
neic hematopoietic stem cell transplantation (allo-HSCT). Because VZV-specific T cell immunity is essential
to prevent virus reactivation, we developed an interferon-g enzyme-linked immunosorbent spot (ELISPOT)
assay for the sensitive detection of VZV-reactive T cells at the single-cell level ex vivo. We used this assay to
monitor the frequency of VZV-reactive T cells in 17 seropositive patients during the first year after T cell–
depleted allo-HSCT. The patients did not receive anti-herpesvirus prophylaxis after stem cell engraftment.
Independent of the magnitude of transferred donor immunity, VZV-reactive T cell numbers decreased to
low levels (median, 2/mL; range, 0 to 35/mL) in peripheral blood early after transplantation. Only patients
with subsequent zoster (n 5 5) exhibited a dramatic boost in VZV-reactive T cells (median, 366/mL; range,
158 to 756/mL), which was induced by the reactivation event. The postzoster VZV-reactive T cell levels were
similar to those seen in healthy virus carriers. In contrast, antiviral T cell levels remained low in patients with-
out VZV disease. Our results demonstrate that VZV-specific T cell immunity recovered efficiently during
zoster in T cell–depleted allo-HSCTrecipients. It did not reconstitute spontaneously in nonzoster patients,
even in the absence of antiviral prophylaxis. Prospective studies should investigate whether VZV vaccination
can substitute for natural resensitization by virus disease.
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Primary infection with varicella-zoster virus
(VZV) causes chickenpox in nearly all humans [1].
Subsequently, the virus establishes life-long latency
in neurons of the cranial and spinal ganglia. VZV can
reactivate from this reservoir and produce herpes zos-ent of Medicine III, Hematology and Oncology, and
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6/j.bbmt.2008.09.004ter, which is associated with pain, scarring, and post-
herpetic neuralgia. If the virus disseminates to the
abdominal cavity or brain, then the infection may be
life-threatening.
Symptomatic VZV reactivation generally results
from a decline in virus-specific cell-mediated immu-
nity, a consequence of immunosenescence or of im-
munosuppressive disease or therapy [2]. The risk of
reactivated disease is greatest in patients who have
undergone allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT), particularly in those treated
with T cell–depleting agents [3,4]; however, herpes
zoster also occurs in T cell–replete HSCT patients,
with an incidence of 25% to 40% [5,6]. Although
acyclovir prophylaxis effectively reduces VZV reacti-
vation, it does not provide complete protection, and
disease may appear several years posttransplantation
[7-10].
VZV-specific T cell immunity appears to be essen-
tial to the prevention and control of VZV reactivation
[2]. This immunity traditionally has been measured in
HSCT patients using proliferation assays [7,9,11-13].1417
1418 Biol Blood Marrow Transplant 14:1417-1424, 2008E. Distler et al.But although these assays can detect cell-mediated im-
mune responses to VZV, they are unable to assess the
precursor frequency of antiviral T cells. Consequently,
we established an interferon (IFN)-g enzyme-linked
immunosorbent spot (ELISPOT) assay that allows
the sensitive detection of VZV-reactive T cells at the
single-cell level in peripheral blood mononuclear cells
(PBMCs) ex vivo. We used this assay to monitor the
frequency of antiviral T cells in 17 seropositive pa-
tients during the first year after T cell–depleted allo-
HSCT. Our results show that VZV-reactive T cells
decreased to very low levels early post-HSCT. These
cells’ in vivo expansion to levels detected in healthy
virus carriers was observed only after symptomatic
VZV disease.METHODS
Patients
The study protocol was designed to prospectively
analyze immune reactivity to VZV in patients with
hematologic malignancies after undergoing T cell–
depleted reduced-intensity allo-HSCT. The pre-
transplantation conditioning regimen comprised
fludarabine (Flu), melphalan (Mel), and the lympho-
depleting antibody alemtuzumab [14]. All of the study
patients had a history of chickenpox before transplan-
tation and were VZV-seropositive. VZV serostatus
also was positive for stem cell donors of sibling origin,
but was unavailable for unrelated stem cell donors. It
was determined by quantitative IgG and qualitative
IgM enzyme-linked immunosorbent assay (Virion-
Serion, Wu¨rzburg, Germany). All patients received
herpesvirus prophylaxis with oral famciclovir (250
mg 3 times daily) until day 130 post-HSCT, but not
thereafter. VZV disease was diagnosed clinically and
was confirmed by VZV polymerase chain reaction. It
responded well to 1-week treatment with intravenous
aciclovir (10 mg/kg body weight 3 times daily), fol-
lowed by oral famciclovir (250 mg 3 times daily) over
3 to 4 weeks. The study was approved by the local
ethics committee and was performed in accordance
with the Declaration of Helsinki. Informed consent
was obtained from all participants.
PBMCs were collected from study patients every 1
to 2months throughout the first year after allo-HSCT.
The 1-year incidence of VZV disease was 35% for all
patients treated in this protocol. The study population
included 5patientswhodeveloped herpes zoster during
the first year after transplantation and 12 patients with
no clinical signs ofVZVreactivation during this period.
The 2 groups did not differ significantly (P. .05; Stu-
dent’s t- test) with regard tomedian age (57 vs 55 years)
andmedian numbers of circulatingCD41Tcells (35 vs
34/mL), CD81 T cells (5 vs 6/mL), and B cells (8 vs 3/
mL) measured at day 150 post-HSCT before onset ofVZVdisease. On the same day, both groups had similar
percentages of mixed donor T cell chimeras (20% vs
33%).Patients 1, 5, 6, 7, 10, 11, and14 receivedprophy-
lactic CD8-depleted donor lymphocyte infusions
(DLIs) [14]. None of the patients developed acute
graft-versus-host disease (aGVHD) grade II-IV or
extensive chronic GVHD (cGVHD) throughout the
observationperiod.None received prednisone therapy.
All patients were treated in the same study protocol,
which scheduled the start of cyclosporine A (CsA) taper
on day135 after related donor transplantations and on
day 175 after unrelated donor transplantations [14].
The zoster and nonzoster groups did not differ in terms
of the proportion of patients requiring prolonged CsA
treatment because of persistent moderate GVHD.
Donor PBMCs analyzed for anti-VZV reactivity
were consistently derived from redundant pilot tubes
of leukapheresis products and were available from the
stem cell donors of patients 1 to 11, 13, and 15. The re-
spective leukaphereseswereperformedwithout preced-
ing granulocyte-colony stimulating factor (G-CSF)
treatment in the donors of patients 1, 5, 6, 7, 10, and
11 to prepare CD8-depleted DLIs [14]. In contrast,
leukapheresis products of the donors for patients 2,
3, 4, 8, 9, 13, and 15 were harvested after G-CSF
mobilization, because they were used for allo-HSCT.
The proportion of donors without G-CSF treatment
was 40% and 50% in the analyzed donor cohorts of
zoster and nonzoster patients, respectively. Because
of this nearly equal distribution, the potential immu-
nosuppressive effects induced by G-CSF were not
expected to differ significantly between both donor
cohorts.IFN-g ELISPOTAssay
IFN-g ELISPOT assays were performed with
cryopreserved PBMCs as described previously [15].
The freezing and thawing procedures were conducted
according to standardized protocols for all PBMC
samples. ELISPOT responders were total PBMCs
(5  105/well) or CD41 and CD81 T cells (1  105/
well) selected from PBMCs using CD4/CD8 micro-
beads (Miltenyi Biotec, BergischGladbach, Germany).
Purified T cells were plated with 1  104/well autolo-
gous monocyte-derived dendritic cells [15]. Cells were
incubated over 40 hours with lysates [15] prepared
from VZV-infected and uninfected Vero cells (each
25 mg/mL), respectively. Infection of Vero cells with
the VZV ROD strain was performed over 7 to 9 days
before lysate production (Advanced Biotechnologies,
Columbia, MD). Positive control wells contained
PBMCs stimulated with 5 mg/mL phytohemagglutinin
(PHA; Murex Pharmaceuticals, Dartford, UK).
To determine the HLA restriction of VZV-
reactive T cells, 100 mg/mL of IgG2a monoclonal an-
tibodies (mAb) for blocking pan-HLA class I (W6/32)
Biol Blood Marrow Transplant 14:1417-1424, 2008 1419Zoster drives posttransplant recovery of VZV-specific T cellsor HLA-DR (L243) were added to the assay medium.
Irrelevant IgG2a isotypes were included as controls.
Antibodies were concentrated from supernatants of
hybridomas purchased from American Type Culture
Collection (Manassas, VA). Spot-forming cell (SFC)
values in the diagrams are means of duplicate or tripli-
cate wells. The frequency of VZV-reactive T cells was
calculated based on SFCs per 5  105 PBMCs of leu-
kapheresis products, or SFCs per mL peripheral
blood. The latter was derived from the SFC count
per 5  105 plated PBMCs and the related PBMC
count per mL of peripheral blood. The PBMC count
was assessed by measuring the percentage of total lym-
phocytes and monocytes in white blood cell differen-
tial analysis. Student’s t-test was used to determine
the significance of the results.
Proliferation Assay
CryopreservedPBMCswere thawed and incubated
at 10e5 cells/well for 6 days with VZV-infected Vero
cell lysate or uninfected control lysate (1 mg/mL
each) in 96-well round-bottomed microtiter plates
in a total volume of 200 mL of AIM-V medium
(GIBCO-BRL, Grand Island, NY) supplemented
with 10% human serum. Wells with medium instead
of lysates or with PHA (5 mg/mL) were used as con-
trols. 3H-thymidine (0.5 mCi/well; AmershamLife Sci-
ence, Braunschweig, Germany) was added 18 hours
before assay termination, and incorporation was mea-
sured with a TopCount scintillation counter (Wallace,
Turku, Finland). The results represent means of tripli-
cates with standard deviations indicated.RESULTS AND DISCUSSION
Frequency Analysis of VZV-Reactive T Cells in
Healthy Virus Carriers
We first established an IFN-g ELISPOT assay to
determine the precursor frequency of VZV-reactive T
cells in PBMCs ex vivo. Given the comparatively low
number of molecularly defined T cell epitopes of
VZV, we used a VZV-infected cell lysate and an unin-
fected control lysate as the antigen sources. Figure 1A
shows that the virus lysate was specifically recognized
by T cells of VZV-seropositive healthy volunteers
in a concentration-dependent manner. Because maxi-
mum reactivity was observed at 25 mg/mL in most
donors, we chose this lysate concentration for all sub-
sequent assays.
Further experiments with anti-HLA–blocking
antibodies and T cell subpopulations demonstrated
that the anti-VZV memory response was dominated
by HLA-class II–restricted CD41 T cells, whereas
VZV-reactive CD81 T cells were not detected
(Figure 1B and C). This finding confirmed the findings
of previous studies that were unable to identify VZV-specific CD81 T cells in immunocompetent donors
by ex vivo analysis, even when oligopeptides and live
viral vaccine were used for stimulation instead of ly-
sates [16,17]. We believe that low numbers of circulat-
ing virus-specific CD81 T cells contribute to viral
persistence, and possibly may reflect immune escape
mechanisms, such as VZV-induced down-regulation
of HLA-class I [18].
We next validated the IFN-g ELISPOT assays in
15VZV-seropositive healthy volunteers who had ame-
dian frequency of 444 (range, 105 to 1134) VZV-reac-
tive T cells/mL of peripheral blood (Figure 2). None
of them recognized the uninfected control lysate
(data not shown). In contrast, VZV-reactive IFN-g
spot production was not observed in 5 seronegative
healthy donors (Figure 2). Altogether, these results
demonstrate the high specificity and sensitivity of the
ELISPOT assay.
Posttransplantation Recovery of VZV-Specific
T Cell Immunity after VZV Disease
We used the IFN-g ELISPOT assay to monitor
the frequency of VZV-reactive T cells in 5 seropositive
patients who developed localized herpes zoster 2 to 7
months after undergoing allo-HSCT (Figure 3). The
pretransplantation preparative regimen of these pa-
tients included T cell depletion with alemtuzumab
and reduced-intensity conditioning (RIC) with Flu
and Mel [14]. Immediately before the onset of clinical
symptoms, the number of circulating antiviral T cells
was extremely low (median, 2/mL; range, 0 to 35/
mL). However, these counts increased dramatically
by . 1-log (median, 366/mL; range, 158 to 756/mL)
within 2 to 4 weeks after zoster manifestation and
remained at elevated levels for several months.
HLA-blocking experiments demonstrated that an-
tiviral CD41 T cells were the main IFN-g producers
in the first weeks after the onset of zoster (Figure 4).
However, we also detected significant VZV reactivity
by CD81T cells during this period. This finding dem-
onstrates that even thoughVZV lysatemay be a subop-
timal antigen format for detecting VZV-specific
CD81 T cells, its use in the ELISPOT assay is suffi-
cient for visualizing antiviral CD8 responses early after
zoster. In contrast to specific T cells, VZV-IgG anti-
body levels did not increase upon zoster onset. Only
patients 1 and 4 generated a VZV-specific IgM re-
sponse (Figure 3). Overall, these findings demonstrate
that B cell stimulation is inferior to T cell stimulation
in response to zoster after allo-HSCT.
VZV-Specific T Cells Do Not Reconstitute
Spontaneously in Nonzoster Patients
Wenext monitored the frequency of VZV-reactive
T cells in 12 seropositive patients who did not develop
symptomatic VZV reactivation during the first year
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Figure 1. VZV lysate is recognized by CD41memory T cells. A, PBMCs derived from VZV-seropositive healthy donor 1 were analyzed for reactivity to
VZV-infected and uninfected Vero cell lysates in an IFN-g ELISPOTassay. Lysates were added at titrated concentrations to the assay medium. Data are
means of duplicate wells and are representative of 6 experiments in 3 different healthy virus carriers. B, CD41 and CD81 T cells were selected from
PBMCs of VZV-seropositive healthy donor 2 and incubated with lysate-loaded autologous dendritic cells in ELISPOT plates. Dendritic cells were induced
to mature after the addition of lysate preparations, which is a suitable strategy for promoting lysate-reactive CD81 T cell responses [15]. C, ELISPOT
reactivity to VZV lysate in PBMCs of seropositive healthy donor 3 was inhibited by monoclonal antibodies with blocking activity against HLA-DR, but not
against HLA-class I. Data in panels B and C are means of triplicate wells and are representative of experiments in 5 different healthy immune donors.
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Intraindividualmeasurements were performed at ame-
dian of 3 time points (range, 1 to 3). Interestingly, none
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Figure 3. Reconstitution of VZV-specific T cell immunity on posttransplantation herpes zoster. Patients 1 to 5 developed zoster during the first year
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SFCs/5 105 PBMCs; P5 .25) (Figures 3 and 5). This
finding indicates that in the setting of T cell depletion,
the VZV-specific T cell frequency in stem cell donors
before transplantation was not predictive of future zos-IFN-γ  spo
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in vivo. This is particularly true for recipients of agents
that cause severe lymphodepletion, such as alemtuzu-
mab. More studies are needed to determine whether
a similar suppression of VZV-specific T cell immunity
occurs in patients after T cell–replete allo-HSCT.
We emphasize that our patients received oral anti-
herpesvirus prophylaxis until day 130 post-HSCT,
but not thereafter. Whether or not such drugs impede
VZV-specific T cell reconstitution by preventing
subclinical viremia was not uniformly answered by 2
previous randomized trials [7,9]; however, the consis-
tently low frequency of antiviral T cells in 12 nonzos-
ter patients suggests that avoiding antiviral prophylaxis
does not necessarily favor the recovery of VZV-spe-
cific T cell immunity. In addition, our results contrast
with earlier reports showing that subclinical viremia
without progression to herpes zoster already may be
sufficient to stimulate VZV-specific T cell prolifera-seropos.
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Figure 6. Detection of VZV reactivity by proliferation assay. PBMCs isolated
from healthy immune and nonimmune donors (HD), were incubated for 6 days w
respectively. Medium and PHA (not shown) served as controls. T cell prolifer
cubation on day 6. Prezoster PBMCswere derived at 2.75 months (patient 1), 0
after HSCT. Postzoster PBMCs were obtained at 4.75 months (patient 1), 3 m
after HSCT. For correlation with ELISPOT data, see Figure 3.tion in a significant proportion of allo-HSCT recipi-
ents [19,20]. Major differences in applied T cell
assays (ie, proliferation and cytotoxicity vs ELISPOT),
as well as the use of vigorous T cell depletion in our pa-
tient cohort, might explain the somewhat contradic-
tory results.
Analysis of VZV-Specific Immune Reactivity by
Proliferation Assay
We decided to also analyze immune reactivity to
the VZV-infected Vero cell lysate by proliferation as-
says in those zoster patients for whom additional
PBMC samples were available. We first adapted
well-established protocols for proliferation assays for
analyzing VZV reactivity [7,9,11-13] to the use of
our lysate preparation. Preliminary experiments
showed that optimal results could be achieved with
an incubation period of 6 days and a VZV lysate con-
centration of 1 mg/mL (data not shown). The assayat 3 
post
Pat 4 
pre post
Pat 5 
pre post
medium
uninfected
VZV-infected
from patients prior to and after disease manifestation, as well as PBMCs
ith 1 mg/mL of VZV-infected Vero cell lysate or uninfected control lysate,
ation was measured by 3H-thymidine uptake for the last 18 hours of in-
.75 month (patient 3), 4.5 months (patient 4), and 2.25 months (patient 5)
onths (patient 3), 6.25 months (patient 4), and 10.75 months (patient 5)
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was seen in PBMCs of VZV-seropositive healthy do-
nors only, and not in those of a seronegative individual
without a history of VZV contact (Figure 6). In addi-
tion, proliferation of PBMCs above background
values was not found in control wells seeded with
the uninfected Vero cell lysate. In subsequent analysis
of zoster patients, we detected VZV lysate-specific
proliferation in postzoster PBMCs from 3 of 4
patients, which was not evident before disease mani-
festation (Figure 6). These results are consistent with
the IFN-g ELISPOT data obtained from the same
PBMC samples (Figure 3). In contrast, patient 4,
who failed to respond to the VZV lysate in the prolif-
eration assay, exhibited minor, but still significant, re-
activity on the ELISPOT assay. This finding
demonstrates the superior sensitivity of the IFN-g
ELISPOT assay, allowing the detection of antigen-
specific T cells at the single-cell level.Conclusions and Potential Applications
Using a newly developed IFN-g ELISPOT assay,
we found an early decrease in VZV-reactive T cells in
the peripheral blood of VZV-seropositive allo-HSCT
recipients. Their low numbers and delayed recovery
most likely were caused by administration of the
lymphocytotoxic antibody alemtuzumab during con-
ditioning therapy [14]. Subsequently, symptomatic
VZV reactivation was required to boost antiviral T
cells to frequencies comparable to those measured in
healthy virus carriers. A similar correlation between
posttransplantation recovery of antiviral T cells and vi-
rus reactivation has been shown for human cytomega-
lovirus (CMV) [21,22]. Our study provides some
indication of the level of circulating VZV-reactive T
cells that may protect against zoster. This conclusion
is derived from the finding of frequencies . 100/mL
in both immunocompetent donors and patients with
zoster. None of the latter developed a second episode
of VZV disease during a median period of 14 months
(range, 12 to 18 months).
Finally, our findings suggest that a vaccination ap-
proach, as a substitute for natural resensitization by vi-
rus reactivation, may help accelerate the reconstitution
of VZV-specific T cell immunity in allo-HSCT recip-
ients [13,23]. The use of our assay in prospective trials
should help to optimize such vaccination strategies and
also help to define a ‘‘threshold’’ frequency of circulat-
ing VZV-reactive T cells that allows for discontinua-
tion of antiviral prophylaxis.ACKNOWLEDGMENTS
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